The industry has experienced a sustained period of change since its blockbuster heyday in the 1990s and continues to evolve, with significant ramifications for new pharmaceutical launches.<
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh